USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
OXFORD BIOMEDICAL RESEARCH, INC.
Address:
2165 AVON INDUSTRIAL DRIVE
ROCHESTER HILLS, MI 48309-
Phone:
(248) 852-8815
URL:
N/A
EIN:
138250649
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,079,708.00 34
SBIR Phase II $6,025,181.00 15
STTR Phase I $85,395.00 1

Award List:

DEVELOPMENT OF ALTERNATIVE, EXOGENOUS METABOLISM SYSTEMS FOR

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Arthur Bull , Principal Investigator
Abstract:
N/a

DEVELOPMENT OF ALTERNATIVE, EXOGENOUS METABOLISM SYSTEMS FOR

Award Year / Program / Phase:
1986 / SBIR / Phase II
Award Amount:
$374,000.00
Agency:
HHS
Principal Investigator:
Arthur Bull , Principal Investigator
Abstract:
The identification of mutagenic compounds is an important societal goal. short-term tests that employ mammalian enzymes (generally mixed-function oxidases from rat liver) to provide metabolic activation of premutagens to ultimate mutagens have been developed for this purpose. it is now clear that… More

PEROXIDASE ACTIVATION

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Arthur w bull, jr , PRINCIPAL INVESTIGATOR
Abstract:
Assays that employ mammalian enzymes (generally mixed- function oxidases from rat liver) to provide metabolic activation of premutagens to ultimate mutagens have been developed and are widely used to identify mutagenic compounds. it is now clear that some compounds are activated by other oxidizing… More

ISOLATION AND PURIFICATION OF PROSTACYCLIN SYNTHASE

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

DEVELOPMENT OF PROBES FOR INVESTIGATION OF ORGANIC ACIDURIAS

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$47,395.00
Agency:
HHS
Principal Investigator:
Ann L Hards
Abstract:
Glutaryl-coa dehydrogenase (gcdh), an enzyme common to lysine, hydroxylysine, and tryptophan catabolism, catalyzes the conversion of glutaryl-coa to crotonyl-coa. lack of gcdh activity in humans is characterized by excretion of massive amounts of glutaric acid and 3-hydroxyglutaric acid, thus… More

ISOLATION AND PURIFICATION OF PROSTACYCLIN SYNTHASE

Award Year / Program / Phase:
1991 / SBIR / Phase II
Award Amount:
$487,390.00
Agency:
HHS
Principal Investigator:
Abstract:
Prostacyclin synthase (pgi2 synthase) catalyzes an intramolecular redox reaction in which prostaglandin endoperoxide, pgh2, is converted to prostacyclin, pgi2. the potent biological activities of pgi2 indicate an important role for prostacyclin synthase in the pathophysiology of thrombosis and… More

HUMAN LIPOXYGENASE PRUFICATION AND MOLECULAR PROBES

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$49,996.00
Agency:
HHS
Principal Investigator:
Krishnamoorthany Sankaran
Abstract:
Lipoxgenases constitute a famly of non-heme iron-containing dioxygenases that have been demonstrated to produce a wide range physiologically active metaboites. the enzyme 12-lipoxygenase (12-lx) is present in platelets, leukosytes, lung and brain. 12-lx converts arachidonic acid to 12-hpete, which… More

Isolation and Purification of Prostaglandin E Isomerase

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$49,984.00
Agency:
HHS
Principal Investigator:
Krishnamoorthy Sankaran
Abstract:
Prostaglandin E isomerase (known as PGE2 synthase also) catalyses the isomerization reaction in which prostaglandin endoperoxide (PGH2) is converted to PGE2. The potent biological activities of PGE2 indicate an important role for prostaglandin E isomerase in the pathogenesis of periodontal disease,… More

Development of Antibodies for Drug Metabolizing Enzymes

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Kim Hyesook
Abstract:
N/a

Immunoassay for A Non-Enzymatic Arachidonate Derivative

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$49,904.00
Agency:
HHS
Principal Investigator:
Krishnamoorthy Sankaran
Abstract:
N/a

Develop Assay for 9,11 3-Hydroxyoctadecadienoic Acid

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
HHS
Principal Investigator:
Ramesh Reddy
Abstract:
Linoleic acid, the predominant polyunsaturated fatty acid (PUFA) in the human diet, can bemetabolized by cyclooxgenase, lipoxygenase and P450 enzymes. The monohydroxy derivatives oflinoleic acid, 9(S)-HODE and 13 (S)-HODE, are the most widely distributed of the known linoleic acidmetabolites. These… More

Molecular Probes for an Oncogene Regulatory Protein

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$80,208.00
Agency:
HHS
Principal Investigator:
Ramesh Reddy
Abstract:
The development of cancer is a complex process that appears to involve multiple mechanisms.Recent studies indicate that the Her-2/neu (ERBB2) gene may be important in the transformation ofnormal breast epithelial cells to a cancerous phenotype. In reality, more than one-half of breast cancersare… More

Immunoassay for A Non-Enzymatic Arachidonate Derivative

Award Year / Program / Phase:
1994 / SBIR / Phase II
Award Amount:
$463,462.00
Agency:
HHS
Principal Investigator:
Krishnamoorthy Sankaran
Abstract:
A novel class of postaglandin F2-like compounds formed in vitro or in vivo by a free-radical catalyzed noncyclocxygenase mechanism have recently been discovered. For normal humans. Levels of these compounds (called F2-isoprostanes) range from 5-50 pg/ml plasma and 500-3000 pg/ml urinary creatinine,… More

Development of Antibodies for Drug Metabolizing Enzymes

Award Year / Program / Phase:
1994 / SBIR / Phase II
Award Amount:
$419,964.00
Agency:
HHS
Principal Investigator:
Kim Hyesook
Abstract:
We will develop and market a comprehensive collection of antibodies specific for enzymes that play a significant role in drug metabolism . Availability of specific antibodies will greatly facilitate studies of polymorphisms, species and tissue distribution of drug metabolizing enzymes, and the role… More

Prostaglandin Synthase-2--Purification and Immunoassay

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$79,759.00
Agency:
HHS
Principal Investigator:
Hyesook Kim
Abstract:
N/a

Assay for 9/13-Hydroxyoctadecadienoic Acid

Award Year / Program / Phase:
1995 / SBIR / Phase II
Award Amount:
$312,618.00
Agency:
HHS
Principal Investigator:
Reddy Ramesh
Abstract:
Linoleic acid, the predominant polyunsaturated fatty acid (PUFA) in the human diet, is a substratecyclooxygenase, lipoxygenase and cytochrome P450 enzymes. The majore metabolitcs of these pathways,13(S)-HODE, 9, 10-epoxyoctadecenoate, and 12, 13-epoxyoctadecenoate are known to exhibit… More

Molecular Probes for An Orphan Eicosanoid Pathway

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$98,171.00
Agency:
HHS
Principal Investigator:
Hyesook Kim
Abstract:
The vast majority of studies on prostanoid metabolism have focused on prostaglandin E2, prostacyclithromboxane A2, and the leukotrienes, which are collectively involved in the regulation of a wide rapathophysiological events. Although it has been the subject of less intense investigation, it has… More

Prostaglandin Synthase-2--Purification and Immunoassay

Award Year / Program / Phase:
1996 / SBIR / Phase II
Award Amount:
$377,998.00
Agency:
HHS
Principal Investigator:
Hyesook Kim
Abstract:
This project will develop methods for large scale production and quantification of humanprostaglandin H synthase-2 (PGHS-2), a recently discovered enzyme that is differentially regulated andhas significantly different properties than the pGHS-1. Data obtained to date in experimental systemssuggest… More

MURINE MONOCHROMOSOMAL HYBRID PANELS

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$88,625.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

SCREENING SYSTEM FOR PROSTANOID RECEPTOR LIGANDS

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$98,668.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

GENOTOXICITY ASSAYS WITH ENDOGENOUS P450 ACTIVATION

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$97,956.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

HUMAN ISOPROSTANE METABOLITES--DETECTING OXIDANT STRESS

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$98,364.00
Agency:
HHS
Principal Investigator:
Sasaki, Diane
Abstract:
N/a

DEVELOPMENT OF IMMUNOASSAYS FOR P450 EICOSANOIDS

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$99,657.00
Agency:
HHS
Principal Investigator:
Sasaki, Diane
Abstract:
N/a

HUMAN ISOPROSTANE METABOLITIES--DETECTING OXIDANT STRESS

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$98,364.00
Agency:
HHS
Principal Investigator:
Sasaki, Diane
Abstract:
N/a

N/A

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$23,960.00
Agency:
HHS
Principal Investigator:
Diane Sasaki
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase II
Award Amount:
$293,994.00
Agency:
HHS
Principal Investigator:
Diane Sasaki
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Diane Susaki
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase II
Award Amount:
$280,000.00
Agency:
HHS
Principal Investigator:
Diane Susaki
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Diane Sasaki
Abstract:
N/a

N/A

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$98,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

N/A

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$99,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

N/A

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

N/A

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$224,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

N/A

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

N/A

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$134,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

NF-KB: A Marker for Cellular Oxidative Stress

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$99,580.00
Agency:
HHS
Principal Investigator:
Smiti V. Gupta
Abstract:
DESCRIPTION (Applicant's abstract): Accumulating evidence suggests oxidative stress is responsible for altered metabolic functions in various pathophysiological conditions including cancer, cardiovascular disease and aging. The production of reactive oxygen… More

Multidimensional Gas Chromatograph for Toxicological An*

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$197,185.00
Agency:
HHS
Principal Investigator:
Diane M. Sasaki
Abstract:
DESCRIPTION (provided by applicant): This project will explore the application of a dual-secondary column comprehensive two-dimensional gas… More

DEVELOPMENT OF SURROGATE BIOMARKERS FOR SAFETY EVALUATION OF CHEMICALS:

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$35,763.00
Agency:
HHS
Principal Investigator:
Thomas Brown
Abstract:
N/a

HUMAN ISOPROSTANE METABOLITES: DETECTING OXIDANT STRESS

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Diane Sasaki
Abstract:
N/a

HUMAN ISOPROSTANE METABOLITES: DETECTING OXIDANT STRESS

Award Year / Program / Phase:
2002 / SBIR / Phase II
Award Amount:
$150,000.00
Agency:
HHS
Principal Investigator:
Diane Sasaki
Abstract:
N/a

MOLECULAR BIOMARKERS/NON-INVASIVE DIAGNOSIS OF COLON CA

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$96,484.00
Agency:
HHS
Principal Investigator:
Abstract:
Colorectal cancer is a leading cause of death in the United States. There is very strong evidence that screening for this disease can reduce colorectal cancer mortality. Present screening methods include fecal occult blood testing (FOBT) and endoscopy, which can detect some early colon cancers and… More

Transcription Factor markers - cellular oxidative stress

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Accumulating evidence suggests that sustained oxidative stress affects many biochemical and molecular processes and is responsible for altered metabolic functions in various pathophysiological conditions including cancer, cardiovascular disease and aging. … More

Transcription Factor markers - cellular oxidative stress

Award Year / Program / Phase:
2003 / SBIR / Phase II
Award Amount:
$496,014.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Accumulating evidence suggests that sustained oxidative stress affects many biochemical and molecular processes and is responsible for altered metabolic functions in various pathophysiological conditions including cancer, cardiovascular disease and aging. … More

N/A

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Diane Sasaki
Abstract:
N/a

N/A

Award Year / Program / Phase:
2003 / SBIR / Phase II
Award Amount:
$138,131.00
Agency:
HHS
Principal Investigator:
Diane Sasaki
Abstract:
N/a

Organ Specific Damage Assessment Biomarker Assays

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Biomarkers that accurately reflect acute and/or past exposure to harmful agents are crucial in any study aiming to reduce the incidence of diseases resulting from environmental chemicals or other exposures. The biomarkers evaluated to date in biological fluids… More

Organ Specific Damage Assessment Biomarker Assays

Award Year / Program / Phase:
2003 / SBIR / Phase II
Award Amount:
$710,033.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Biomarkers that accurately reflect acute and/or past exposure to harmful agents are crucial in any study aiming to reduce the incidence of diseases resulting from environmental chemicals or other exposures. The biomarkers evaluated to date in biological fluids… More

QCM Quantification of Endocrine Disruptor Activity

Award Year / Program / Phase:
2004 / STTR / Phase I
Award Amount:
$85,395.00
Agency:
HHS
Principal Investigator:
Research Institution:
OAKLAND UNIVERSITY
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Environmental agents with estrogen-like activity are a major public health issue. Although a variety of assays have been developed to detect binding to the estrogen receptor (ER) and other assays have been developed to monitor subsequent effects on estrogen… More

Advanced GST Proteomics for Early Stage Organ-Specific Toxicity Screening

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$117,685.00
Agency:
HHS
Principal Investigator:
Kevin M. Patrie – 248-852-8815
Abstract:
DESCRIPTION (provided by applicant): Current biomarkers employed in the detection of organ toxicity are often not sensitive enough to detect the early stages of acute organ damage, i.e. at a stage when reducing or eliminating exposure to a toxin could prevent progression of organ damage or a disease… More

Advanced GST Proteomics for Early Stage Organ-Specific Toxicity Screening. Phase

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$1,163,577.00
Agency:
HHS
Principal Investigator:
Kevin M. Patrie – 248-852-8815
Abstract:
DESCRIPTION: Biomarkers currently employed for the detection of organ toxicity are often not sensitive enough to detect the early stages of acute organ damage, i.e. at a stage when reducing or eliminating exposure to a toxin could prevent progression of organ damage or a disease process, nor do… More